B
Benjamin Movsas
Researcher at Fox Chase Cancer Center
Publications - 129
Citations - 7206
Benjamin Movsas is an academic researcher from Fox Chase Cancer Center. The author has contributed to research in topics: Radiation therapy & Lung cancer. The author has an hindex of 44, co-authored 129 publications receiving 6990 citations. Previous affiliations of Benjamin Movsas include Vanderbilt University & Kyungpook National University.
Papers
More filters
Journal ArticleDOI
Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.
Miljenko V. Pilepich,Kathryn Winter,Colleen A. Lawton,Robert E. Krisch,Harvey B. Wolkov,Benjamin Movsas,Eugen B. Hug,Sucha O. Asbell,David J. Grignon +8 more
TL;DR: In a population of patients with unfavorable prognosis carcinoma of the prostate, androgen suppression applied as an adjuvant after definitive RT was associated not only with a reduction in disease progression but in a statistically significant improvement in absolute survival.
Journal ArticleDOI
Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions
Gerald E. Hanks,Alexandra L. Hanlon,Timothy E. Schultheiss,Wayne H. Pinover,Benjamin Movsas,Barry E. Epstein,Margie A. Hunt +6 more
TL;DR: The improvement in 5-year bNED rates for patients with PSA levels > 10 ng/ml strongly suggests that clinical trials employing radiation should investigate the use of 3DCRT and prostate doses of 76-80 Gy.
Journal ArticleDOI
Pulmonary Radiation Injury
Journal ArticleDOI
Phase III comparison of sequential vs concurrent chemoradiation for pts with unresected stage III non-small cell lung cancer (NSCLC): Report of Radiation Therapy Oncology Group (RTOG) 9410
Walter J. Curran,Charles B. Scott,Corey J. Langer,R.U. Komaki,Jangsoon Lee,Stephen L. Hauser,Benjamin Movsas,Todd H. Wasserman,Anthony H. Russell,R. Byhardt,William T. Sause,James D. Cox +11 more
Journal ArticleDOI
A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104.
Kevin Murray,Charles E. Scott,Harvey Greenberg,Bahman Emami,Michael I. Seider,Nayana Vora,Craig Olson,Anthony Whitton,Benjamin Movsas,Walter J. Curran +9 more
TL;DR: In this paper, the authors compared 1-year survival and acute toxicity rates between an accelerated hyperfractionated (AH) radiotherapy (1.6 Gy b.i.d.) to a total dose of 54.4 Gy in 14 fractions.